These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18725477)

  • 1. REVIEW paper: pathophysiology of myocardial reperfusion injury: the role of genetically engineered mouse models.
    Ramachandran A; Jha S; Lefer DJ
    Vet Pathol; 2008 Sep; 45(5):698-706. PubMed ID: 18725477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury.
    Vinten-Johansen J
    Cardiovasc Res; 2004 Feb; 61(3):481-97. PubMed ID: 14962479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signalling pathways in ischaemic postconditioning.
    Hausenloy DJ
    Thromb Haemost; 2009 Apr; 101(4):626-34. PubMed ID: 19350104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process.
    Moens AL; Claeys MJ; Timmermans JP; Vrints CJ
    Int J Cardiol; 2005 Apr; 100(2):179-90. PubMed ID: 15823623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of adenosine as adjunctive therapy in acute myocardial infarction.
    Forman MB; Stone GW; Jackson EK
    Cardiovasc Drug Rev; 2006; 24(2):116-47. PubMed ID: 16961725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin protects from reperfusion-induced myocardial injury by enhancing coronary endothelial nitric oxide production.
    Mihov D; Bogdanov N; Grenacher B; Gassmann M; Zünd G; Bogdanova A; Tavakoli R
    Eur J Cardiothorac Surg; 2009 May; 35(5):839-46; discussion 846. PubMed ID: 19237290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction.
    Salio M; Chimenti S; De Angelis N; Molla F; Maina V; Nebuloni M; Pasqualini F; Latini R; Garlanda C; Mantovani A
    Circulation; 2008 Feb; 117(8):1055-64. PubMed ID: 18268142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of cardioprotective effect of ischemic pre- and postconditioning in the hyperhomocysteinemic rat heart.
    Balakumar P; Rohilla A; Singh G; Singh K; Singh M
    Methods Find Exp Clin Pharmacol; 2009 Mar; 31(2):71-9. PubMed ID: 19455261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium.
    Gawaz M
    Cardiovasc Res; 2004 Feb; 61(3):498-511. PubMed ID: 14962480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synthetic pentasaccharide fondaparinux prevents coronary microvascular injury and myocardial dysfunction in the ischemic heart.
    Montaigne D; Marechal X; Lancel S; Decoster B; Asseman P; Neviere R
    Thromb Haemost; 2008 Nov; 100(5):912-9. PubMed ID: 18989538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of oxidants and free radicals in reperfusion injury.
    Zweier JL; Talukder MA
    Cardiovasc Res; 2006 May; 70(2):181-90. PubMed ID: 16580655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of zinc-bis-(DL-hydrogensaspartate) does not reduce apoptotic cell death in myocardial infarction in the rat heart.
    Schwarz ER; Tussing T; Skobel E; Klosterhalfen B; Domanski D; Fuess JE
    J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):215-21. PubMed ID: 19605571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microvascular dysfunction following primary percutaneous coronary intervention in the setting of ST-elevation myocardial infarction.
    Ramaraj R; Movahed MR
    J Invasive Cardiol; 2008 Nov; 20(11):603-14. PubMed ID: 18987402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between ischemia-reperfusion injury, myocardial stunning and cardiac preconditioning.
    Mitchell MB; Winter CB; Banerjee A; Harken AH
    Surg Gynecol Obstet; 1993 Jul; 177(1):97-114. PubMed ID: 8322165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of reperfusion beyond infarct size limitation.
    Takemura G; Nakagawa M; Kanamori H; Minatoguchi S; Fujiwara H
    Cardiovasc Res; 2009 Jul; 83(2):269-76. PubMed ID: 19176600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of the no-reflow phenomenon.
    Vrints CJ
    Acute Card Care; 2009; 11(2):69-76. PubMed ID: 19526383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocardial infarction: animal models.
    Chimenti S; Carlo E; Masson S; Bai A; Latini R
    Methods Mol Med; 2004; 98():217-26. PubMed ID: 15064443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury.
    Steffens S; Montecucco F; Mach F
    Thromb Haemost; 2009 Aug; 102(2):240-7. PubMed ID: 19652874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute myocardial infarction and myocardial ischemia-reperfusion injury: a comparison.
    Hashmi S; Al-Salam S
    Int J Clin Exp Pathol; 2015; 8(8):8786-96. PubMed ID: 26464621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient metabolic alkalosis during early reperfusion abolishes helium preconditioning against myocardial infarction: restoration of cardioprotection by cyclosporin A in rabbits.
    Pagel PS; Krolikowski JG
    Anesth Analg; 2009 Apr; 108(4):1076-82. PubMed ID: 19299764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.